Takla Anja, Wichmann Ole, Koch Judith, Terhardt Martin, Hellenbrand Wiebke
Immunization Unit, Robert Koch Institute, Seestrasse 10, 13353 Berlin, Germany.
Primary care pediatrician, Düsseldorfer Strasse 75, 40878 Ratingen, Germany.
Vaccine. 2014 Nov 12;32(48):6349-55. doi: 10.1016/j.vaccine.2014.09.040. Epub 2014 Oct 1.
Incidence of invasive meningococcal disease is low in Germany at 0.5 cases/100,000 inhabitants. Serogroup B (MenB) is most common, causing 70% of cases, with highest incidence in infants (5.9/100,000). In 2013, a MenB vaccine was licensed in Europe. To assess pediatricians' attitudes towards MenB vaccination and its potential use in Germany we conducted a nationwide cross-sectional survey among 5677 pediatricians. Of 3107 participants (response: 55%), 79.1% would recommend a MenB vaccination to parents, with 66.7% favoring a schedule at 6, 8 and 12 months over 2, 3, 4 and 12 months (13.4%). Administration separately from other vaccines was preferred (63.2%); 38.5% feared that a recommendation would lead to refusal of other recommended vaccinations. In conclusion, pediatricians showed distinct preferences regarding possible integration of MenB vaccination into the existent immunization schedule. As physicians play a crucial role in the implementation, findings will be useful in decision-making regarding potential introduction.
侵袭性脑膜炎球菌病在德国的发病率较低，为每10万居民0.5例。B群（MenB）最为常见，导致70%的病例，在婴儿中的发病率最高（每10万例中有5.9例）。2013年，一种MenB疫苗在欧洲获得许可。为评估儿科医生对MenB疫苗接种的态度及其在德国的潜在用途，我们对5677名儿科医生进行了一项全国性横断面调查。在3107名参与者中（回复率：55%），79.1%的人会向家长推荐MenB疫苗接种，66.7%的人倾向于在6个月、8个月和12个月的接种计划，而不是在2个月、3个月、4个月和12个月的接种计划（13.4%）。与其他疫苗分开接种更受青睐（63.2%）；38.5%的人担心推荐会导致拒绝其他推荐的疫苗接种。总之，儿科医生在将MenB疫苗接种纳入现有免疫接种计划的可能性方面表现出明显的偏好。由于医生在实施过程中起着关键作用，研究结果将有助于在潜在引入方面的决策。
